Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer

References

• Wong SM, Freedman RA, Sagara Y, et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265:581–589.
   PubMed Web of Science ®Google Scholar
• Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. JCO. 2007;25:5203–5209.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Lichtensztajn DY, Keegan TH, et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA. 2014;312:902–914.
   PubMed Web of Science ®Google Scholar
• Kiely BE, Jenkins MA, McKinley JM, et al. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Res Treat. 2010;120:715–723.
   PubMed Web of Science ®Google Scholar
• Neuburger J, Macneill F, Jeevan R, et al. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open. 2013;3:e003179.
   PubMed Web of Science ®Google Scholar
• Guth U, Myrick ME, Viehl CT, et al. Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol. 2012;38:296–301.
   PubMed Web of Science ®Google Scholar
• Wang F, Amara D, Peled AW, et al. Negative genetic testing does not deter contralateral prophylactic mastectomy in younger patients with greater family histories of breast cancer. Ann Surg Oncol. 2015;22:3338–3345.
   PubMed Web of Science ®Google Scholar
• van Driel CMG, Oosterwijk JC, Meijers-Heijboer EJ, et al. Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees. Breast. 2016;30:66–72.
   PubMed Web of Science ®Google Scholar
• Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152:274–282.
   PubMed Web of Science ®Google Scholar
• Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4:CD002748.
   PubMed Web of Science ®Google Scholar
• Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.
   PubMed Web of Science ®Google Scholar
• Hunt KK, Euhus DM, Boughey JC, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol. 2017;24:375–397.
   PubMed Web of Science ®Google Scholar
• Reiner AS, John EM, Brooks JD, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. JCO. 2013;31:433–439.
   PubMed Web of Science ®Google Scholar
• Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. JCO. 2004;22:1823–1829.
   PubMed Web of Science ®Google Scholar
• Wright FC, Look Hong NJ, Quan ML, et al. Indications for contralateral prophylactic mastectomy: a consensus statement using modified delphi methodology. Ann Surg. 2018;267:271–279.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cunningham AP, Kuchenbaecker KB, Consortium of Investigators of Modifiers of B, Breast Cancer Association C, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110:535–545.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39:22–25.
   PubMed Web of Science ®Google Scholar
• Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4:103.
   Web of Science ®Google Scholar
• Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77:342–349.
   PubMed Web of Science ®Google Scholar
• Uyei A, Peterson SK, Erlichman J, et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006;107:2745–2751.
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Kjaer SK, Ejlertsen B, et al. Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. Int J Epidemiol. 2014;43:1855–1864.
   PubMed Web of Science ®Google Scholar
• Katz SJ, Janz NK, Abrahamse P, et al. Patient reactions to surgeon recommendations about contralateral prophylactic mastectomy for treatment of breast cancer. JAMA Surg. 2017;152:658.
   PubMed Web of Science ®Google Scholar
• Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019.
   Web of Science ®Google Scholar
• Elsayegh N, Webster RD, Gutierrez Barrera AM, et al. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018;7:2718–2726.
   PubMed Web of Science ®Google Scholar